Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

GlobeNewswire July 6, 2022

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

GlobeNewswire July 6, 2022

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

GlobeNewswire June 24, 2022

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

GlobeNewswire June 21, 2022

SHAREHOLDER ALERT: Weiss Law Reminds VEC, LLNW, VMW, and EBS Shareholders About Its Ongoing Investigations

PR Newswire June 3, 2022

Emergent BioSolutions to Participate in Investor Conferences

GlobeNewswire June 2, 2022

SHAREHOLDER ALERT: Weiss Law Reminds EBS, NFLX, RDBX, and TREC

PR Newswire May 25, 2022

SHAREHOLDER ALERT: Weiss Law Reminds EBS, NFLX, RDBX, and TREC

PR Newswire May 18, 2022

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

GlobeNewswire May 16, 2022

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

GlobeNewswire May 12, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.

PR Newswire May 10, 2022

Emergent BioSolutions Reports Financial Results For First Quarter 2022

GlobeNewswire April 28, 2022

Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022

GlobeNewswire April 8, 2022

Emergent BioSolutions Provides Corporate Governance Update

GlobeNewswire March 23, 2022

Emergent BioSolutions to Participate in Investor Conferences

GlobeNewswire March 14, 2022

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

GlobeNewswire March 11, 2022

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021

GlobeNewswire February 24, 2022

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022

GlobeNewswire February 7, 2022

Founder and Executive Chairman of Emergent BioSolutions Announces Retirement

GlobeNewswire January 14, 2022

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

GlobeNewswire January 9, 2022